FINANCIAL TRUST COMPANY INC ACCT.
For the Period 3/1/12 to 3/31/12
Note P indicates position adjusted for Pending Trade Activity.
Unrealized GainLoss is shown as "N A" in cases where we do not have appropriate cost information for all lax lots comprising the position. Please contact your J P Morgan team for additional
information.
Equity Detail
Adjusted Tax Cost Unrealized Est. Annual Inc
Price Quantity Value Original Cost Gain toss Accrued Div. Yield
US Large Cap Equity
ARIAD PHARMACEUTICALS INC 15.98 16,535.000 264,229.30 251,475.52 12,753.78
04033A-10-0 ARIA
BIOGEN IDEC INC 126.00 2095 000 263,970.00 250,454.95 13,515.05
09062X-10-3 BIIB
DB CONT BUFF E0 MS 08/07/12 91.64 1.009.000 000 916,400.00 1,000,000.00 (83,600.00)
25% CONTIN BARRIER- 1 3%CPN
30% CAP
INITIAL LEVEL-07,1511 MS 21 09
2515A1-A7-6
P DOLLAR GENERAL CORP 46.20 MOO
256677-10-6 DG
P DUNIUN BRANDS GROUP INC 30.06 0.00 1.99%
265504-10-0 DNKN
HSBC MARKET PLUS SPX 06117/13 102.72 5,000,000.000 5,136,000.00 5,000,000.00 136.000.00
72% KO BARRIER- 096CPN
,UNCAPPED
INITIAL LEVEL-02/14/12 SPX:1350.50
4042K1-XQ-1
JP Morgan Account Page 5 of 32 Consolidated Statement Page 8
Confidential Treatment Requested by JPMorgan JPM-SDNY-00015736
Chase
CONFIDENTIAL SDNY_GM_00284934
EFTA01492917